Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 10,369 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 10,369 shares of the stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $43.01, for a total transaction of $445,970.69. Following the completion of the transaction, the insider directly owned 71,155 shares of the company’s stock, valued at $3,060,376.55. This trade represents a 12.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

David Malcom Rodman also recently made the following trade(s):

• On Monday, September 15th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $36.00, for a total transaction of $409,212.00.
• On Wednesday, August 13th, David Malcom Rodman sold 11,365 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $12.93, for a total value of $146,949.45.

Mineralys Therapeutics Trading Up 1.3%

MLYS stock opened at $43.35 on Thursday. Mineralys Therapeutics, Inc. has a 1-year low of $8.24 and a 1-year high of $44.38. The firm has a market cap of $2.87 billion, a P/E ratio of -12.18 and a beta of 0.40. The business’s 50 day moving average is $29.55 and its 200-day moving average is $19.58.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.12. Sell-side analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on MLYS shares. Bank of America increased their target price on shares of Mineralys Therapeutics from $38.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. Wall Street Zen raised shares of Mineralys Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Wednesday, October 8th. Wells Fargo & Company boosted their target price on Mineralys Therapeutics from $26.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday, September 11th. Finally, Jefferies Financial Group lifted their price objective on Mineralys Therapeutics from $15.00 to $26.00 and gave the company a “hold” rating in a research report on Wednesday, September 3rd. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.50.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of large investors have recently modified their holdings of the stock. Wellington Management Group LLP raised its position in Mineralys Therapeutics by 32.8% in the 1st quarter. Wellington Management Group LLP now owns 121,557 shares of the company’s stock worth $1,930,000 after purchasing an additional 30,028 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Mineralys Therapeutics by 9,602.2% in the 1st quarter. GAMMA Investing LLC now owns 8,829 shares of the company’s stock valued at $140,000 after buying an additional 8,738 shares during the period. Voya Investment Management LLC acquired a new stake in shares of Mineralys Therapeutics in the 1st quarter valued at $255,000. Strs Ohio acquired a new stake in shares of Mineralys Therapeutics in the 1st quarter valued at $359,000. Finally, Goldman Sachs Group Inc. boosted its holdings in Mineralys Therapeutics by 166.6% in the first quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company’s stock valued at $4,739,000 after acquiring an additional 186,480 shares during the last quarter. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.